Understanding: What It Takes

What it really takes to bring a new strain to market

In the first instalment of this series, “Finding the One”, we explored how a plant earns its place, not through novelty, but through balance.
Structure. Maturity. Resin. Aroma.

But “finding the one” is only the beginning.

Because in medical cannabis, selection is not the finish line. It is the starting point for something far more demanding…

Proving that what you’ve found can be repeated.

The reality of pheno-hunting

Pheno-hunting is often romanticised. Rows of plants. Endless variation. The thrill of discovery… And that part is real… But what is less visible is the attrition.

“For every plant you keep, there are dozens you don’t.”

As explored in “Finding Identity”, most plants never make it beyond selection;  not because they are poor, but because they are not the right fit.

The process begins wide:

• multiple phenotypes
• broad genetic variation
• different expressions of the same cultivar

Each is assessed across:

• structure
• aroma
• resin production
• growth behaviour
• environmental response

And then, gradually, the field narrows; Not toward the most extreme expression, but toward the most balanced and repeatable one.

Selection is about defining what “good” looks like

In many contexts, the “best” plant is the most obvious:

• the largest
• the fastest
• the most visually striking

But in a medical setting, “good” is defined differently; it is not just about how a plant looks once. It is about how it behaves, consistently, within a system.

“You’re not selecting the most impressive plant. You’re selecting the one you can rely on.”

— Brady, Head Grower

Pheno-hunting is not about removing character; It is about identifying the phenotype that best aligns:

• desirable sensory attributes (aroma, structure, resin)
• with the requirements of a compliant, scalable crop

This is not compromise. It is alignment. A plant that is highly expressive but unstable will not translate into a consistent product.

“There are plenty of plants that look great once. Far fewer that look great every time.”

— Brady, Head Grower

Outliers are not removed because they are poor; they are removed because they introduce variability and variability, at scale, becomes risk.

From plant to mother

Once a phenotype has proven itself, it becomes something else entirely:

A mother plant.

This is the point where cultivation becomes replication. Every clone, every cycle, every batch traces back to this decision, which means that decision must withstand:

• environmental variation
• scale
• time

“When you pick a mother, you’re committing to that decision thousands of times over.”

— Brady, Head Grower

There is no room for uncertainty!

Scaling changes everything

A plant that performs well in isolation does not always perform at scale and a plant that performs in one room does not always perform across many.

Scaling introduces pressure:

• small inconsistencies compound
• environmental sensitivity increases
• variability becomes systemic

“Anyone can grow a good plant once. The challenge is growing the same plant, over and over again.”

— Brady, Head Grower

This is why consistency must be proven across multiple cycles, not just once.

Time, uncertainty, and cost

This process takes time. A cultivar cannot be validated in a single run, it must be proven across multiple cycles under controlled conditions.

From initial pheno-hunt to production-ready cultivar can take:

• 9–12 months
• multiple full cultivation runs
• repeated testing and evaluation

During this time, the market does not stand still. Preferences shift, new products emerge, demand evolves. This means decisions are often made months,  sometimes a year,  before a product reaches a patient. Alongside time, there is cost.

Running multiple cycles, allocating space to trial cultivars, and committing resources to something that may never be released carries significant financial weight. It is not uncommon for the cost of bringing a single cultivar to market to exceed £100,000+ before it is ever prescribed

“You’re investing time, space and resource into something that might never make it. That’s just part of the process.”

— Brady, Head Grower

What do you grow for… The market, or the unknown?

There is another layer to this process, and it is not technical, it is strategic.

In “Understanding Diversity”, we explored how markets often claim to want broad diversity, yet in practice tend to converge around familiar genetic profiles. This is not because innovation isn’t valued, but because familiarity is, which creates a tension.

Do you select for what is already understood, or do you push toward something less proven, but potentially more meaningful?

“You can grow something completely unique,  but if no one understands it, it won’t go anywhere.”

— Brady, Head Grower

The challenge is that this decision is made long before the market ever sees the product.

“You’re not just growing for today. You’re trying to predict where things will be by the time it’s ready.”

— Brady, Head Grower

The result is not a binary choice, it is a balance between:

• the familiar and the unfamiliar
• the proven and the exploratory
• what is consumed today, and what might be needed tomorrow

Because in a medical context, novelty alone is not enough.

But nor is repetition.

The unseen craft: drying and curing

If cultivation defines potential, drying and curing define outcome and this is where shortcuts are most tempting and most costly.

At Dalgety, this is a process we refuse to rush. Plants are harvested and hung until moisture content reaches a defined threshold. Only then are they transferred (still on the stem) into bags for an initial cure, followed by:

• trimming
• a second curing phase
• stabilisation before release

“You can’t make up for lost time after harvest. What you do in those first days defines everything that follows.”

— Brady, Head Grower

Time here is not inefficiency. It is control.

Uniformity over spectacle

In many markets, quality is judged visually; large flowers, dense structure, immediate impact; and while we are always pleased to hear that patients have received some of the largest flowers they’ve encountered, this is not the objective.

Uniformity is.

A canopy that behaves predictably, a crop that matures evenly, a batch that performs consistently.

“You’re not growing for the biggest cola. You’re growing for a room where everything behaves the same way.”

— Brady, Head Grower

Because consistency is what allows a product to be understood by clinicians and by patients.

What it really takes

To bring a new strain to market is not to introduce something new, it is to remove uncertainty. To take a complex, variable plant and shape it into something that can be:

• measured
• repeated
• relied upon

This takes time. It takes restraint. It takes a willingness to discard more than you keep, because in the end, the goal is not to find the most interesting plant. It is to find the one that can be trusted.

In cannabis, discovery is exciting. But in medicine, consistency is everything.